Patents by Inventor Bruce H. Frank

Bruce H. Frank has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5952297
    Abstract: The present invention discloses various parenteral pharmaceutical formulations having a protracted effect, which comprise: a sterile aqueous suspension of about 20 U/mL to about 500 U/mL insulin analog, about 5 mg/mL to about 10 mg/mL sodium chloride, about 0.2 to about 2.0 mg/mL physiologically acceptable buffer, a zinc ion content of about 0.07 mg/mL to about 0.1 mg/mL, and a physiologically acceptable preservative at a pH of about 6.5 to about 7.8; such that less than 5% of the analog present in the suspension is in the dissolved state.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: September 14, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael R. De Felippis, Bruce H. Frank
  • Patent number: 5700662
    Abstract: Recombinant processes for preparing insulin analogs modified at position 29 of the B-chain and, optionally, at other positions are claimed. The analogs produced using the claimed processes have modified physico-chemical properties and are useful in treating hyperglycemia.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 23, 1997
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Chance, Richard D. DiMarchi, Bruce H. Frank, James E. Shields
  • Patent number: 5547929
    Abstract: The present invention discloses various parenteral pharmaceutical formulations, which comprise a mixture of a monomeric insulin analog and insulin-NPH. The analog formulations provide a rapid onset and a prolonged duration of action.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: August 20, 1996
    Assignee: Eli Lilly and Company
    Inventors: James H. Anderson, Jr., Michael R. De Felippis, Bruce H. Frank, Henry A. Havel
  • Patent number: 5514646
    Abstract: Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.
    Type: Grant
    Filed: May 5, 1993
    Date of Patent: May 7, 1996
    Inventors: Ronald E. Chance, Richard D. DiMarchi, Bruce H. Frank, James E. Shields
  • Patent number: 5504188
    Abstract: The present invention discloses a process of preparing a crystalline insulin analog. The process is useful in the purification and manufacture of Lys.sup.B28 Pro.sup.B29 -human insulin. Lys.sup.B28 Pro.sup.B29 -human insulin is useful in the treatment of diabetes.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: April 2, 1996
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey C. Baker, Nancy D. Carter, Bruce H. Frank
  • Patent number: 5474978
    Abstract: The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: December 12, 1995
    Assignee: Eli Lilly and Company
    Inventors: Diane L. Bakaysa, David N. Brems, Bruce H. Frank, Henry A. Havel, Allen H. Pekar
  • Patent number: 5457066
    Abstract: This specification describes a process for converting a human insulin precursor to human insulin, which comprises treating such human insulin precursor with trypsin and carboxypeptidase B in an aqueous medium containing per mole of human insulin precursor from about 0.1 to about 10 moles of one or more metal ions of those metals having Atomic Numbers 21 to 34, 39 to 52, 57 to 84, and 89 to 92.
    Type: Grant
    Filed: May 11, 1992
    Date of Patent: October 10, 1995
    Assignee: Eli Lilly and Company
    Inventors: Bruce H. Frank, Walker E. Prouty, Richard E. Heiney, Mark R. Walden
  • Patent number: 4654324
    Abstract: A pharmaceutical composition which comprises human proinsulin in association with a pharmaceutically acceptable carrier is useful in controlling a diabetic condition and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.
    Type: Grant
    Filed: December 17, 1984
    Date of Patent: March 31, 1987
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Chance, Bruce H. Frank, John A. Galloway
  • Patent number: 4652547
    Abstract: A pharmaceutical composition which comprises, in association with a pharmaceutically acceptable carrier, human insulin and human proinsulin in a weight ratio, human insulin to human proinsulin, of from about 1:100 to about 100:1, is useful in treating diabetics and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.
    Type: Grant
    Filed: December 17, 1984
    Date of Patent: March 24, 1987
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Chance, Bruce H. Frank, John A. Galloway
  • Patent number: 4652548
    Abstract: A pharmaceutical composition which comprises, in association with a pharmaceutically acceptable carrier, human insulin, human C-peptide, and human proinsulin, said human C-peptide being present in a molar ratio, human insulin to human C-peptide, of from about 1:4 to about 4:1, and said human proinsulin being present in a weight ratio, human insulin to human proinsulin, of from about 1:100 to about 100:1, is useful in treating diabetics and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.
    Type: Grant
    Filed: December 17, 1984
    Date of Patent: March 24, 1987
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Chance, Bruce H. Frank, John A. Galloway
  • Patent number: 4581165
    Abstract: A class of compounds having insulin-like activity is described. These compounds have the formula ##STR1## in which X is --OH, -Arg-Arg-OH, or -Arg-Arg-Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-G ly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-OH.
    Type: Grant
    Filed: June 14, 1984
    Date of Patent: April 8, 1986
    Assignee: Eli Lilly and Company
    Inventors: Bruce H. Frank, Allen H. Pekar
  • Patent number: 4569792
    Abstract: A class of compounds having insulin-like activity is described. These compounds have the formula ##STR1## in which X is --OH, -Ala-Leu-Glu-Gly-Ser-Leu-Gln-OH, or -Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg-OH.
    Type: Grant
    Filed: June 14, 1984
    Date of Patent: February 11, 1986
    Assignee: Eli Lilly and Company
    Inventors: Bruce H. Frank, Allen H. Pekar
  • Patent number: 4569791
    Abstract: A class of compounds having insulin-like activity is described. These compounds have the formula ##STR1## in which n is zero or one.
    Type: Grant
    Filed: June 14, 1984
    Date of Patent: February 11, 1986
    Assignee: Eli Lilly and Company
    Inventors: Bruce H. Frank, Allen H. Pekar
  • Patent number: 4430266
    Abstract: A proinsulin-like disulfide insulin precursor is produced from its corresponding linear chain S-sulfonate insulin precursor by reacting the S-sulfonate with a mercaptan in an amount which provides from about 1 to about 5 --SH moieties per --SSO.sub.3.sup.- moiety in an aqueous medium at a pH of from about 7 to about 11.5 and at an S-sulfonate concentration of up to about 10 mg. per ml. of aqueous medium.
    Type: Grant
    Filed: February 16, 1982
    Date of Patent: February 7, 1984
    Assignee: Eli Lilly and Company
    Inventor: Bruce H. Frank